“Skin Clearance, Duration of Treatment-Free Interval, and Safety of Tapinarof Cream 1% Once Daily: Results from ADORING 3, a 48-Week Phase 3 Trial in Adults and Children Down to 2 Years of Age With Atopic Dermatitis”. SKIN The Journal of Cutaneous Medicine, vol. 9, no. 2, Mar. 2025, p. s553, https://doi.org/10.25251/skin.10.supp.553.